Thursday, March 26, 2009
The most expensive drugs now on the market could have to compete with lower-cost generic versions just five years after launching, under a new congressional proposal.
A bipartisan bill introduced in the Senate aims to reduce the cost of biotech drugs, high-tech injectable medicines that can cost thousands of dollars per month.
Efforts to create a pathway for generic biotech drugs have been bogged down for years by disagreements between biotech and generic drugmakers.
But with President Obama and other Democrats pushing the issue as a cost saver, the generic drug industry is poised to realize its long-sought goal: a speedy path to market for lower-cost biotech.